Bavarian Nordic secures another deal with undisclosed European country for 1.5M Jynneos doses

Just after Bavarian Nordic inked a deal with the U.S. for an additional 2.5 million doses of the smallpox and monkeypox vaccine Jynneos, an undisclosed European country has ordered an additional 1.5 million doses.

The jabs, called Imvanex in Europe, will be delivered starting this year. The majority of doses will be delivered throughout 2023, leading the company to keep its recently increased financial outlook for the year.

Paul Chaplin, the company’s president and CEO, applauded governments for “thinking beyond the current situation and building stockpiles to secure future preparedness,” Manufacturing Chemist reports.

Bavarian Nordic has already secured deals of varying sizes with multiple undisclosed countries, ensuring that there is “significant supply” to vaccinate people at risk of infection, according to previous statements. Many countries were scrambling to ensure a stockpile of the vaccines.

The orders have boosted the Danish drugmaker’s revenue forecasts more than once. Recently, a 110,000-dose order from the European Health Emergency Preparedness and Response Authority (HERA) spurred an increase in the company's revenue outlook, although it's still expected to chart an overall loss due to R&D investments for the year.

Aside from the HERA order as well as orders from the U.S. and other undisclosed countries, the company has also inked deals with Canada to deliver shots.

The smallpox vaccine has been shown to be 85% effective against monkeypox. The U.S. has a stockpile of more than 100 million doses of another smallpox shot produced by Emergent BioSolutions called ACAM2000, but that vaccine carries a higher risk of side effects.